Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.
This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 26 June.
On the agenda this time are Pfizer Inc. and Sanofi’s coronavirus development plans and policies, what increased use of dexamethasone might mean for Indian pharma, Boehringer Ingelheim International GmbH’s M&A strategy, and an infographic on the state of global biopharma R&D.
Stories mentioned in this episode:
(Also see "Pfizer’s Bourla On COVID-19 Vaccine: "There Is No ROI That Will Drive Our Decision"" - Scrip, 22 Jun, 2020.)
(Also see "Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy" - Scrip, 23 Jun, 2020.)
(Also see "Is Dexamethasone The Next HCQ For Indian Pharma?" - Scrip, 19 Jun, 2020.)
(Also see "Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire" - Scrip, 19 Jun, 2020.)
(Also see "The 2020 Worldwide Pharma & Biotech Industry R&D Scene" - Scrip, 24 Jun, 2020.)